---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Incidence"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Incidence. Topics: United States: incidence of diagnosed CSU in three US databases, 2012 to 2018, Novartis-funded; United States: combined adult and pediatric incidence of diagnosed CSU and annual trend, Novartis-funded study; United States: average annual incidence of diagnosed CSU of 0.08% in HealthVerity claims, 2017 to 2022, Novartis-affiliated authors; United States: chronic urticaria incidence estimate in the Joint Task Force practice parameter; 3 further topics. 7 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/incidence"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Incidence

<a id="heading-2.2.1.2.1"></a>

## 2.2.1.2.1 Incidence of Chronic spontaneous urticaria

<a id="topic-2.2.1.2.1-1"></a>

### United States: incidence of diagnosed CSU in three US databases, 2012 to 2018, Novartis-funded

> “This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.”
> “The data identification period for Optum EHR and Optum CDM was from January 1, 2012 to December 31, 2018, and for MarketScan it was January 1, 2012 to December 31, 2017.”
> “The target population was identified using three anonymized databases: Optum Electronic Health Record (EHR), Optum Clinformatics Data Mart (CDM), and Truven Health MarketScan.”
> “Incident cohorts included newly identified patients with the first urticaria or angioedema code within the year of interest and no codes 12 months prior to that year.”
> “In Optum EHR, the age- and sex-standardized incidence rate (95% CI) among adults and pediatric patients during the identification period was 0.039 (0.039–0.039) and 0.066 (0.065–0.067) per 100 person-years, respectively”
> “The age-standardized incidence rate (95% CI) of CSU among the adult and pediatric populations during the identification period in Optum CDM was 0.094 (0.093–0.095) and 0.109 (0.107–0.111) per 100 person-years, respectively”
> “In MarketScan, the age-standardized incidence rate (95% CI) of CSU among adults and pediatric patients during the identification period was 0.102 (0.097–0.107) and 0.097 (0.096–0.098) per 100 person-years, respectively”
> “The study also reports for the first time, to the best of our knowledge, standard incidence rate of diagnosed CSU in the USA, with period estimates among adults ranging from 0.039 to 0.102 per 100 person-years in the three databases.”
> “This research was funded by Novartis Pharma AG, Basel, Switzerland.”

Source: [Geissbühler et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12085360/)

<a id="topic-2.2.1.2.1-2"></a>

### United States: combined adult and pediatric incidence of diagnosed CSU and annual trend, Novartis-funded study

> “This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.”
> “The sex-standardized combined (adult and pediatric) incidence rate and prevalence (95% CI) were 0.096 (0.096–0.097) per 100 person-years and 0.283% (0.281–0.284), respectively.”
> “The sex-standardized combined (adult and pediatric) incidence rate and prevalence (95% CI) were 0.088 (0.087–0.088) per 100 person-years and 0.244% (0.243–0.245), respectively.”
> “The annual incidence rate ranged from 0.031 in 2012 to 0.069 per 100 person-years in 2018 across the three databases.”
> “Comparatively, the incidence and prevalence were higher among pediatric patients than adults.”
> “This research was funded by Novartis Pharma AG, Basel, Switzerland.”

Source: [Geissbühler et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12085360/)

<a id="topic-2.2.1.2.1-3"></a>

### United States: average annual incidence of diagnosed CSU of 0.08% in HealthVerity claims, 2017 to 2022, Novartis-affiliated authors

> “Adults with a record of CSU diagnosis within the US HealthVerity claims database were eligible.”
> “Age- and gender-adjusted prevalence/incidence rates were calculated for January 2017 to December 2022.”
> “The average annual incidence rate was 0.08%.”
> “US Medical Affairs, Novartis Pharmaceuticals Corp, East Hanover, New Jersey”

Source: [Riedl et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39694087/)

<a id="topic-2.2.1.2.1-4"></a>

### United States: chronic urticaria incidence estimate in the Joint Task Force practice parameter

> “These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma & Immunology.”
> “The incidence of CU has been estimated at 1.4% per year.”

Source: [Bernstein et al. (2014)](https://doi.org/10.1016/j.jaci.2014.02.036)

<a id="topic-2.2.1.2.1-5"></a>

### Italy: incidence of CSU in a general practitioner database, 2002 to 2013

> “The study population was formed by patients aged ≥ 15 years, registered with a total of 700 general practitioners, homogeneously distributed across Italy.”
> “The annual prevalence and incidence rates of CSU over a 12-year period (2002-2013) were estimated, along with demographic and clinical determinants.”
> “The incidence was 0·10-1·50 per 1000 person-years.”
> “For both prevalence and incidence rates, female patients outnumbered male.”

Source: [Lapi et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26872037/)

<a id="topic-2.2.1.2.1-6"></a>

### Italy: incidence of newly diagnosed CSU in primary care, 2002 to 2022

> “A cohort of patients aged 15 years and older with newly diagnosed CSU was identified from Italian primary care data from January 1, 2002, to September 30, 2022.”
> “The incidence was 2.07-1.93 per 1000 person-years.”
> “A cohort of 7,018 patients with CSU was identified during the study period.”

Source: [Lapi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42702025/)

<a id="topic-2.2.1.2.1-7"></a>

### Global: urticaria incidence in the Global Burden of Disease 2021 study

> “We utilized data from the Global Burden of Disease (GBD) Results (2021) to obtain prevalence, incidence, and disability-adjusted life years (DALYs) for urticaria from 1990 to 2021, categorized by age, gender, and region.”
> “Regarding incidence, the total number of urticaria cases rose from 84,870,288 (74,471,430 − 96,206,256) in 1990 to 117,014,587 (104,106,688 − 131,017,656) in 2021.”
> “The incidence rate declined from 1591.23 (1396.26-1803.77) per 100,000 population in 1990 to 1482.82 (1319.25-1660.27) in 2021, with an EAPC value of 0.01 (0.01–0.02).”
> “As shown in Fig. 1 , across all age groups, females generally have higher incidence and DALYs compared to males.”
> “Projections indicate a continued rise through 2046.”

Source: [Tan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12333250/)

| Region | Age-standardized incidence rate, 1990 | Age-standardized incidence rate, 2021 |
| --- | --- | --- |
| High-income North America | “1569.62 (1461.56-1669.2)” | “1602.35 (1507.35-1697.23)” |
| Global | “1529.24 (1355.9-1720.36)” | “1533.71 (1358.35-1726.07)” |

Source: [Tan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12333250/)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
